Oncocyte Corp (OCX) SEC Filing 8-K Material Event for the period ending Monday, September 30, 2019

Oncocyte Corp

CIK: 1642380 Ticker: OCX

View differences made from one to another to evaluate Oncocyte Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Oncocyte Corp.


Assess how Oncocyte Corp's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Oncocyte Corp's Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


Ticker: OCX
CIK: 1642380
Form Type: 8-K Corporate News
Accession Number: 0001493152-19-014917
Submitted to the SEC: Wed Oct 02 2019 7:38:03 PM EST
Accepted by the SEC: Thu Oct 03 2019
Period: Monday, September 30, 2019
Industry: In Vitro And In Vivo Diagnostic Substances
  1. Change in Assets
  2. Financial Exhibit
  3. New Agreement
  4. Regulated Disclosure

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: